Pomalidomide Synthesis via Recrystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing pomalidomide in the pharmaceutical industry face challenges such as low yields, high costs, and inefficiencies in scalability, particularly due to the use of chromatography and low-temperature processes, which hinder the production of high-purity optically active forms at industrial scales.
Innovation Solution
A novel method involving the reaction of compound 18 with compound 19 in the presence of a base, using pyridine or its derivatives, at controlled temperatures, to produce pomalidomide with high yield and purity, utilizing a two-step process that includes recrystallization for enhanced purity, compliant with pharmaceutical industry standards.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chromatography and low-temperature processes are used, then HPLC purity is improved, but productivity and scalability deteriorate
Solution Approach 1:
The invention extracts and eliminates the chromatography step from the synthesis pathway. Instead of using chromatography for purification, the method employs a recrystallization process that achieves the required HPLC purity (>98%) without the need for chromatographic separation, thereby dramatically improving productivity and scalability for industrial production.
Solution Approach 2:
The invention changes the purification parameter from chromatographic separation to recrystallization-based purification. By optimizing the recrystallization conditions (solvent selection, temperature control, cooling rate), the method achieves high HPLC purity through crystal formation and filtration, avoiding the productivity limitations of chromatography.
2Manufacturing precision
If multiple synthesis steps are used, then HPLC purity is improved, but total yield deteriorates
Solution Approach 1:
The invention segments the synthesis into two distinct optically active pathways (Route 1 for S-isomer, Route 2 for R-isomer), each with optimized step sequences. This segmentation allows for targeted purification strategies and minimizes unnecessary steps, achieving >98% HPLC purity while maintaining total yield above 85% for each enantiomer.
Solution Approach 2:
The invention introduces optically active intermediates (such as (S)- or (R)-1-phenylethylamine, or enzymatically resolved compounds) as mediators to achieve stereoselective synthesis. These intermediates enable direct formation of the desired enantiomer with high optical purity, eliminating the need for multiple purification steps and associated yield losses.
3Stability of the object's composition
If conventional synthesis pathways are used, then optical activity is achieved, but cost-effectiveness deteriorates
Solution Approach 1:
The invention incorporates preliminary resolution of chiral intermediates using cost-effective methods (such as diastereomeric salt formation with inexpensive chiral amines or enzymes) before the main synthesis steps. This preliminary action establishes optical purity early in the pathway, preventing the need for expensive chiral chromatography or repeated resolution steps later, thereby improving cost-effectiveness while maintaining optical activity.
Solution Approach 2:
The invention employs inexpensive chiral resolving agents (such as (S)- or (R)-1-phenylethylamine, or readily available enzymatic catalysts) that can be used in stoichiometric or catalytic amounts and then removed or recycled. These cheap chiral auxiliaries enable cost-effective optical resolution without requiring expensive chiral stationary phases or complex chiral pool starting materials.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves a yield of 96.6% with 99.90% HPLC purity, meeting pharmaceutical industry purity requirements and being cost-effective and scalable, with the option for further purity enhancement through recrystallization, resulting in a product identical to the commercially available Form A.
Implementation Method 1
compound 18 or its acid addition salt is reacted with compound 19 in the presence of a base
Implementation Method 2
The compound of general formula 20 thus obtained is used in a condensation reaction with glutamine... optionally followed by recrystallization
Implementation Method 3
The compound of general formula 20 thus obtained is used in a condensation reaction with glutamine, its open chain or cyclic derivative or the metal salt of any of these
Data Source
Figure 1
AI summary
The object of the invention relates to a novel group of compounds of general formula 20 that may be used as an intermediate for the production of the pharmaceutical active substance pomalidomide. The object of the invention also relates to a novel, cost-effective, productive method for the production of pomalidomide that can also be implemented on industrial scales via the novel compound of formula 20 according to the invention.